Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

BUILDING A BUSINESS

Differentiated dollars

Building your startup with venture philanthropy investment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Growth in US disease foundation research investments and in principal sources of US healthcare R&D investment, 2002–2017.
Fig. 2: US R&D investment growth rates, 2002–2017.
Fig. 3: Venture philanthropy investment spectrum.

References

  1. Cause IQ. Medical disease and disorder focused nonprofits. https://www.causeiq.com/directory/disease-focused-nonprofits-list/ (accessed 6 January 2022).

  2. Kim, E. & Lo, A. Venture philanthropy: a case study of the Cystic Fibrosis Foundation. Preprint at SSRN https://doi.org/10.2139/ssrn.3376673 (2019).

  3. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2019 Annual Report (Cystic Fibrosis Foundation, 2020).

  4. Crunchbase. Polaris Partners. https://www.crunchbase.com/organization/polaris-partners (accessed 30 April 2021).

  5. Merck. Merck to acquire Pandion Therapeutics. https://www.merck.com/news/merck-to-acquire-pandion-therapeutics/ (2021).

  6. American Association for Cancer Research. Financial report (AACR, 2020).

  7. Research America. 2002 Investment in US Health Research (Research America, 2002).

  8. Research America. US Investments in Medical Health and Research Development (Research America, 2019).

Download references

Acknowledgements

We thank Sean Doherty, Katie Ellias and Amy Montalto for agreeing to participate in our case studies and providing access to the senior management team of JDRF T1D Fund. We thank Ansbert Gadicke and Chris Bardon for agreeing to participate in our case studies and providing access to the senior management team of MPM, and Kirsten Laguerre and Kellie Neville for helpful comments. We thank Ned Sheetz, Greg Donaldson, and Laura Sol for agreeing to participate in our case studies and providing access to the senior management team of American Heart Association and Aphelion Capital. We thank the many executives who generously provided their time to participate in interviews and wished to remain anonymous so as to speak freely. We thank Jayna Cummings and Shannon McCarthy for their editorial feedback throughout the writing process. The views and opinions expressed in this article are those of the authors only, and do not necessarily represent the views and opinions of any institution or agency, any of their affiliates or employees, or any of the individuals acknowledged above. The information presented is made available solely for general informational purposes and does not constitute endorsement, recommendation or favoring by MIT or the authors. Neither MIT nor the authors warrant the accuracy, completeness or usefulness of this information. Any reliance you place on such information is strictly at your own risk.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Daniel L. Alvarez or Andrew W. Lo.

Ethics declarations

Competing interests

A.W.L. is co-founder of QLS Advisors, LLC, a healthcare analytics and investment advisory company. A.W.L. also invests in and advises a number of biopharma companies that may collaborate with venture philanthropists (the complete list of his investments and advisory positions is available on his website at https://alo.mit.edu/). A.W.L. is an advisor to the American Cancer Society’s BrightEdge Impact Fund, a venture philanthropic organization, and the National Center for Advancing Translational Sciences, a government organization that collaborates with venture philanthropic organizations. A.W.L. has also collaborated with other venture philanthropic organizations on prior research and case studies, including the Cystic Fibrosis Foundation and the National Brain Tumor Society. D.L.A. reports no competing interests.

Supplementary Information

Supplementary Information

Supplementary Note.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alvarez, D.L., Lo, A.W. Differentiated dollars. Nat Biotechnol 40, 458–462 (2022). https://doi.org/10.1038/s41587-022-01260-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01260-y

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing